This post will be closed automatically in 2026-08-03 06:42
Reward10points
https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(20)30637-9/abstractCarboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer: a randomised, phase 3 trialSandro Pignata 1, Domenica Lorusso 2, Florence Joly 3, Ciro Gallo 4, Nicoletta Colombo 5, Cristiana Sessa 6, Aristotelis Bamias 7, Vanda Salutari 8, Fr谷d豕ric Selle 9, Simona Frezzini 10, Ugo De Giorgi 11, Patricia Pautier 12, Alessandra Bologna 13, Michele Orditura 14, Coraline Dubot 15, Angiolo Gadducci 16, Serafina Mammoliti 17, Isabelle Ray-Coquard 18, Elena Zafarana 19, Enrico Breda 20, Laure Favier 21, Antonio Ardizzoia 22, Saverio Cinieri 23, R谷my Largillier 24, Daniela Sambataro 25, Emmanuel Guardiola 26, Rossella Lauria 27, Carmela Pisano 28, Francesco Raspagliesi 29, Giovanni Scambia 8, Gennaro Daniele 30, Francesco Perrone 31; MITO16b/MANGO每OV2/ENGOT每ov17 Investigators
Collaborators, Affiliations expand
|
|